5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Marksans Pharma Ltd.

•
marksanspharma.comBSE: 524404NSE: MARKSANS
Market Cap₹ 14,877 Cr.
Current Price
High / Low₹ 350 / 155
Stock P/E46.2
Book Value₹ 38
Price to Book4.32
Dividend Yield0.27 %
ROCE25.9 %
ROE19.8 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 25.0% CAGR over last 5 years
  • Company is almost debt free
  • Latest quarter profit grew 43.6% YoY, showing strong momentum
  • Company has delivered good sales growth of 17.5% CAGR over last 5 years
  • Company generates healthy free cash flow
  • Company has a consistent dividend-paying track record

CONS

  • A large part of profit comes from other income (26.4% of PBT)
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.44x)
  • Though reporting repeated profits, the company pays out little dividend (13.6%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.MARKSANS328.3028.7914877.370.27159.41173.89840.8035.6121.1025.34
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
182205241225255309312299320320340362321
155167199191213245260248250248264256248
Operating Profit273742344163525270727510673
OPM %14.70%18.22%17.39%15.06%16.21%20.55%16.57%17.29%21.91%22.49%22.21%29.31%22.72%
3316112820317258162717
Interest0000000000000
Depreciation5887777888999
Profit before Tax5444353842767550641218212490
Tax %18.75%29.69%26.91%14.09%24.30%17.20%25.78%24.67%24.41%17.85%25.82%26.09%23.68%
Net Profit443125333263553848100619269
0.980.690.560.730.711.391.220.831.062.201.342.031.52

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
2162954244336006586558531,1741,3411,343
2022663613624865455827139661,0181,016
Operating Profit1429637111411473140208324326
OPM %6.34%9.89%14.93%16.49%18.97%17.27%11.14%16.40%17.72%24.12%24.31%
187803142796266104119
Interest48775441111
Depreciation151291215181729293435
Profit before Tax12175653124135132172243392418
Tax %3.36%25.37%22.13%28.11%20.87%22.69%22.09%22.18%22.60%23.20%23.12%
Net Profit1212443898104103134188301322
EPS0.280.301.070.932.402.542.482.954.156.64—
Dividend Payout %17.72%16.47%4.69%10.80%10.40%9.84%22.03%20.33%19.26%13.56%—

COMPOUNDED SALES GROWTH

10 Years:
14%
5 Years:
17%
3 Years:
27%

COMPOUNDED PROFIT GROWTH

10 Years:
15%
5 Years:
25%
3 Years:
43%

STOCK PRICE CAGR

10 Years:
22%
5 Years:
36%
3 Years:
46%
1 Year:
89%

RETURN ON EQUITY

10 Years:
11%
5 Years:
15%
3 Years:
15%
Last Year:
20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Aug 20

₹ 0.90

Rs.0.9000 per share(90%)Final Dividend

2025

Aug 1

₹ 0.80

Rs.0.8000 per share(80%)Final Dividend

2024

Sep 17

₹ 0.60

Rs.0.6000 per share(60%)Final Dividend

2023

Jun 7

₹ 0.50

Final Dividend

2022

Aug 19

₹ 0.25

Rs.0.2500 per share(25%)Final Dividend

2021

Sep 15

₹ 0.25

Rs.0.2500 per share(25%)Final Dividend

2020

Sep 22

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2018

Sep 19

₹ 0.05

Rs.0.0500 per share(5%)Dividend

2017

Sep 19

₹ 0.05

Rs.0.0500 per share(5%)Dividend

2016

Sep 22

₹ 0.12

Rs.0.1200 per share(12%)Dividend

2015

Sep 23

₹ 0.12

Rs.0.1200 per share(12%)Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital41414141414145454545
3783884304655596511,0661,1771,3381,604
847687131395789
Trade Payables213437576474112160204181
2221303584215141159201217
Total Liabilities5465606256107619891,3691,5481,7962,056
9488103115129136144272383398
Capital Work in Progress0000004000
234236236236236237266293266267
2942707594104131191205189
0000000370550623
Cash & Bank3123106224440312269447
185193214181196290384111123131
Total Assets5465606256107619891,3691,5481,7962,056

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
2203311812788833431211
Cash from Investing-8-8-20-249-128-195-11417-140
Cash from Financing21-101-82-1471210-26-30-39
-1-212102-167-1061832

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
43.8743.8743.8743.8743.8743.8743.8743.8743.87
18.5921.3121.9522.1919.8916.928.1316.7617.47
3.754.104.304.565.505.285.916.576.19
Government0.000.000.000.000.000.000.000.000.00
33.7830.7129.8729.3730.7533.9342.0932.7932.47

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-07
Copy of Newspaper Publication

2026-09-07 - Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF

2026-09-01
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-01 - Marksans Pharma Limited has informed the Exchange about Schedule of Investors Meet

2026-08-27
Shareholders meeting

2026-08-27 - Marksans Pharma Limited has submitted the Exchange a copy Srutinizers report along with voting result of Annual General Meeting held on August 27, 2026.

2026-08-27
Shareholders meeting

2026-08-27 - Marksans Pharma Limited has informed the Exchange regarding Proceedings of 34th Annual General Meeting held on August 27, 2026

2026-08-26
General Updates

2026-08-26 - Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ESG score by Crisil ESG Ratings & Analytics Ltd

2026-08-20
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-20 - Marksans Pharma Limited has informed the Exchange about Transcript of Investors/Analyst meet Q1 FY 27 Financial Results

2026-08-13
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-13 - Marksans Pharma Limited has informed the Exchange about Link of Recording of Conference call Q1 FY 27 Financial Results

2026-08-13
Copy of Newspaper Publication

2026-08-13 - Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited financial results for the quarter ended June 30, 2026

2026-08-12
Press Release

2026-08-12 - Marksans Pharma Limited has informed the Exchange regarding a press release dated August 12, 2026, titled "Press Release dated 12 August 2026 on the unaudited financial results of the Company for the quarter ended 30 June 2026".

News

Recent coverage and analyst commentary for MARKSANS

Loading news…

🤖

AI Stock Analyst

Marksans Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login